Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Provide Testing for BioMarin Program in Mexico

NEW YORK – BioMarin has chosen PerkinElmer to provide testing in support of the biopharmaceutical firm's sponsored testing program for patients in Mexico, PerkinElmer said on Wednesday.

Specifically, the testing program is aimed at Batten disease and mucopolysaccharidosis (MPS)  disorders and is designed to help patients and clinicians by providing tests for identifying MPS IVA, also called Morquio A syndrome; MPS VI, or Maroteaux-Lamy syndrome; and CLN2, or late infantile neuronal ceroid lipofuscinosis type 2 disease.

PerkinElmer will provide biochemical and genetic testing to patients in Mexico suspected of having Batten disease or an MPS condition, with funding provided by BioMarin. Patients in San Rafael, California-based BioMarin's testing program will receive biochemical screening, followed by confirmatory genetic testing as necessary. All testing will use dried blood spots, Waltham, Massachusetts-based PerkinElmer said.

Financial and other terms of the agreement were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.